Discribe immunization shedule
Reading File
Searching the Web
immunization schedule 2025 WHO CDC recommended vaccines children adults
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have thorough information from multiple authoritative sources. Here is the complete, detailed response:
Immunization Schedule
An immunization schedule is the timed plan for administering vaccines to individuals - designed to provide protection at the earliest and most immunologically appropriate ages, maximizing efficacy while minimizing risk.
Principles Behind the Schedule
- Vaccines are recommended for the youngest age at risk for which the vaccine is safe and effective
- Maternal antibody interference determines timing for live vaccines (e.g., MMR given after 9 months due to transplacental antibody waning)
- Multiple doses are needed when a single dose does not guarantee seroconversion in all recipients (e.g., 1 dose of MMR is 93% effective against measles; 2 doses raise this to ~97%)
- Simultaneous administration of different vaccines is safe, reduces missed visits, and does not impair most immune responses
- Two live-virus vaccines not given on the same day must be separated by at least 28 days
- Interruption of a schedule does not require restarting from the beginning
(Red Book 2021, p. 128)
India - National Immunization Schedule (NIS 2020)
For Pregnant Women
| Vaccine | When to Give | Dose | Route |
|---|---|---|---|
| TT/Td - 1 | Early in pregnancy | 0.5 ml | Intramuscular |
| TT/Td - 2 | 4 weeks after TT-1 | 0.5 ml | Intramuscular |
| TT/Td Booster | If 2 doses given in previous pregnancy within 3 years | 0.5 ml | Intramuscular |
For Infants and Children
| Vaccine | When to Give | Dose | Route | Site |
|---|---|---|---|---|
| BCG | At birth (up to 1 year) | 0.1 ml (0.05 ml if <1 month) | Intradermal | Left upper arm |
| Hepatitis B (birth dose) | At birth, within 24 hours | 0.5 ml | Intramuscular | Anterolateral mid-thigh |
| OPV-0 | At birth, within 15 days | 2 drops | Oral | - |
| OPV 1, 2 & 3 | 6 weeks, 10 weeks, 14 weeks | 2 drops | Oral | - |
| Pentavalent 1, 2 & 3 (DPT + Hep B + Hib) | 6 weeks, 10 weeks, 14 weeks | 0.5 ml | Intramuscular | Anterolateral mid-thigh |
| PCV (Pneumococcal) | 6 weeks, 14 weeks + booster at 9 months | 0.5 ml | Intramuscular | - |
| IPV (Inactivated Polio) | 14 weeks + booster at 16-18 months | 0.1 ml | Intradermal | - |
| Measles (MR) - 1st dose | 9-12 months | 0.5 ml | Subcutaneous | Right upper arm |
| Measles (MR) - 2nd dose | 16-24 months | 0.5 ml | Subcutaneous | Right upper arm |
| DPT Booster 1 | 16-18 months | 0.5 ml | Intramuscular | Anterolateral mid-thigh |
| OPV Booster | 16-18 months | 2 drops | Oral | - |
| Vitamin A (supplementation) | 9 months (100,000 IU); then 200,000 IU every 6 months until 5 years | - | Oral | - |
| DPT Booster 2 | 5 years | 0.5 ml | Intramuscular | Upper arm |
| OPV Booster | 5 years | 2 drops | Oral | - |
| TT | 10 years, 16 years | 0.5 ml | Intramuscular | Upper arm |
(Park's Textbook of Preventive and Social Medicine, Table 43)
IAP (Indian Academy of Pediatrics) Schedule - Additional Vaccines
| Vaccine | Schedule |
|---|---|
| BCG | Birth to 2 weeks |
| OPV | Birth; 6, 10, 14 weeks; 16-18 months; 5 years |
| DPT | 6, 10, 14 weeks; 16-18 months; 5 years |
| Hepatitis B | Birth, 6 weeks, 14 weeks (or 6, 10, 14 weeks) |
| Hib Conjugate | 6, 10, 14 weeks |
| Measles | 9 months, 16-24 months |
| MMR | 15 months |
| Typhoid | 2, 5, 8, 12 years |
| TT/Td | 10 years, 16 years |
After Discussion with Parents (Optional)
| Vaccine | When |
|---|---|
| Varicella | 15 months (or after 1 year) |
| Hepatitis A | 18 months, then 6 months later |
| PCV | 6 weeks onwards |
| Influenza | 6 months onwards, annually (high-risk) |
(Park's Textbook of Preventive and Social Medicine)
WHO EPI (Expanded Programme on Immunization) Global Schedule
| Age | Vaccines |
|---|---|
| Birth | BCG, OPV-0, Hepatitis B |
| 6 weeks | DTP-1, OPV-1 (or IPV-1), Hep B-2, Hib-1, PCV-1, Rotavirus-1 |
| 10 weeks | DTP-2, OPV-2, Hep B-3, Hib-2, PCV-2, Rotavirus-2 |
| 14 weeks | DTP-3, OPV-3 (or IPV), Hib-3, PCV-3, Rotavirus-3 |
| 9 months | Measles-1 (MCV1), Yellow Fever (in endemic areas) |
| 15-18 months | Measles-2 (MCV2) |
The WHO schedule is a framework. Countries adapt it based on disease burden, local epidemiology, and resources.
CDC / USA Schedule (2025 Update)
Children and Adolescents (0-18 years)
| Age | Vaccines |
|---|---|
| Birth | Hep B (dose 1) |
| 1-2 months | Hep B (dose 2) |
| 2 months | DTaP, IPV, Hib, PCV15/PCV20, Rotavirus |
| 4 months | DTaP, IPV, Hib, PCV, Rotavirus |
| 6 months | DTaP, IPV, Hib, PCV, Hep B (dose 3), Influenza (annual from here) |
| 6-18 months | COVID-19 (updated formula) |
| 12-15 months | MMR (dose 1), Varicella (dose 1), Hep A (dose 1), Hib booster, PCV booster |
| 15-18 months | DTaP booster |
| 18-23 months | Hep A (dose 2) |
| 4-6 years | DTaP (dose 5), IPV (dose 4), MMR (dose 2), Varicella (dose 2) |
| 11-12 years | Tdap, HPV series (2 doses if starting before age 15), Meningococcal ACWY |
| 16 years | Meningococcal ACWY booster; MenB (shared decision-making) |
Adults (2025 CDC Key Updates)
| Vaccine | Recommendation |
|---|---|
| Influenza | 1 dose annually (HD-IIV3, RIV3, or aIIV3 preferred for age ≥65) |
| COVID-19 | 1+ dose of 2024-2025 formula; ≥65 years: 2 or more doses |
| Tdap/Td | 1 dose Tdap (if not yet received), then Td booster every 10 years |
| Pneumococcal (PCV) | Lowered from age 65 to age 50 (2025 update) |
| RSV | Adults 50-59 at increased risk: 1 dose (2025 update); age ≥60: 1 dose |
| Shingles (Zoster) | 2 doses RZV at age ≥50 |
| HPV | Through age 26 routinely; ages 27-45 by shared decision-making |
| Hepatitis B | All unvaccinated adults |
(CDC 2025 Immunization Schedule; PALTmed CDC 2025 Update)
Special Notes
- Contraindications: Minor illness (low-grade fever, mild diarrhea, mild respiratory infections) are NOT contraindications - especially important in malnourished children who need vaccination most.
- Catching up: Missed doses do not require restarting the schedule - resume from where you left off.
- Combination vaccines: Pentavalent (DPT + Hep B + Hib) replaces three separate injections in the NIS.
- Live vaccines: If not given simultaneously, must be separated by ≥28 days.
- Immunocompromised patients: Live vaccines are generally contraindicated; inactivated vaccines may need extra doses and titer checks.
Sources:
- Park's Textbook of Preventive and Social Medicine (NIS Table 43, IAP Schedule)
- Red Book 2021: Report of the Committee on Infectious Diseases (AAP), p. 128
- CDC 2025 Child/Adolescent Immunization Schedule
- CDC 2025 Adult Immunization Schedule
Find latest clinical guidelines on immunization in immunocompromised patients
Reading File
Searching PubMed
immunization immunocompromised patients guidelines
Finding Sources
Searching the Web
clinical guidelines vaccination immunocompromised patients 2024 2025 IDSA CDC ACIP
Reading Web Page
vaccination immunocompromised patients recommendations timing live vaccines contraindications
Reading File
Searching PubMed
vaccines immunocompromised HIV transplant cancer recommendations
Reading File
Reading Article
Reading Article
I now have comprehensive data from the IDSA 2025 guidelines, Red Book 2021, and recent meta-analyses. Here is the full synthesized response:
Immunization in Immunocompromised Patients: Latest Clinical Guidelines
Primary Source: IDSA 2025 Guidelines (Nellore A et al., Clin Infect Dis, published March 2, 2026, doi:10.1093/cid/ciag114) - the most current authoritative guidance.
General Principles
The safety and effectiveness of vaccines in immunocompromised patients depends critically on the nature and degree of immunosuppression. Two broad categories apply:
- Primary immune deficiencies - inherited; may involve B cells, T cells, complement, or phagocytes
- Secondary immune deficiencies - acquired; from HIV, malignancy, transplantation, immunosuppressive drugs, or chronic disease
Key universal rules:
- Live vaccines are generally contraindicated in severely immunocompromised patients (risk of vaccine-strain infection)
- Inactivated vaccines are safe but may have reduced immunogenicity
- Timing relative to immunosuppression determines vaccine efficacy - vaccinate before therapy whenever possible
- Household contacts must be kept up to date to reduce transmission risk (cocooning strategy)
(Red Book 2021, p. 190)
Vaccine Contraindications by Immunodeficiency Type
| Category | Example Conditions | Contraindicated Vaccines | Notes |
|---|---|---|---|
| B-cell (humoral) - severe | X-linked agammaglobulinemia, CVID | OPV, BCG, smallpox, LAIV, yellow fever, live-bacteria vaccines | Effectiveness of all vaccines uncertain; annual IIV is the only routinely given vaccine on IG replacement therapy |
| B-cell (humoral) - less severe | Selective IgA deficiency, IgG subclass deficiency | OPV, BCG, yellow fever | All inactivated and live-virus vaccines on standard schedule are safe and should be given |
| T-cell - complete | SCID, complete DiGeorge syndrome | ALL live-bacteria and live-virus vaccines (including rotavirus) | All inactivated vaccines probably ineffective; IG replacement may be needed |
| T-cell - partial | Most DiGeorge, hyperIgM, Wiskott-Aldrich, ataxia-telangiectasia | All live-bacteria and live-virus vaccines | May give MMR/varicella if CD3+ T lymphocytes ≥500/mm³, CD8+ ≥200/mm³, and normal mitogen response |
| Complement deficiency | Terminal complement deficiency, properdin deficiency | None specific | MenACWY recommended; higher meningococcal risk |
| Phagocytic | Chronic granulomatous disease (CGD) | BCG, live-bacteria vaccines | Otherwise can receive most vaccines |
| HIV - no severe immunosuppression | CD4 ≥15% (age <13) or ≥200/mm³ (≥14 yrs) | MMRV (4-in-1), OPV | MMR and monovalent varicella can be given |
| HIV - severe immunosuppression | CD4 <15% or <200/mm³ | All live vaccines | Use only inactivated vaccines |
(Red Book 2021, Table 1.17, p. 190)
IDSA 2025 Guidelines: Respiratory Virus Vaccines in Immunocompromised Patients
1. COVID-19 Vaccination
Recommendation: All adults and children with compromised immunity should receive an age-appropriate 2025-2026 COVID-19 vaccine.
Strength: Strong | Evidence: Moderate certainty
| Population | Suggested Timing |
|---|---|
| Solid organ transplant (SOT) | At least 2 weeks pre-SOT; or ≥3 months post-SOT |
| Hematologic malignancy | Optimal timing coordinated with oncology |
| Hematopoietic cell transplant (HCT) | Generally restart vaccine series post-transplant |
| Immunocompromised <65 years, moderate/severe | Receive updated seasonal dose + consider additional doses under shared decision-making |
| All immunocompromised ≥65 years | ≥2 doses of 2025-2026 formula |
Supporting evidence: A 2024 meta-analysis of allogeneic HCT recipients found a pooled seroconversion rate of 74% after 3 COVID-19 vaccine doses - and 49% seroconversion even in initial 2-dose non-responders, supporting additional doses in this population. [PMID: 38415523]
Key remark: Household contacts and close contacts of immunocompromised patients should also remain up-to-date with COVID-19 vaccination.
2. Influenza Vaccination
Recommendation: All adults and children with compromised immunity should receive age-appropriate 2025-2026 influenza vaccine annually.
Strength: Strong | Evidence: Moderate certainty
| Population | Timing Guidance |
|---|---|
| Solid organ transplant | ≥2 weeks pre-SOT; or ≥1 month post-SOT (may give earlier if influenza season is active) |
| HCT recipients | Generally ≥6 months post-transplant |
| Active cancer treatment | Avoid during most intense periods of acute transplant rejection treatment or severe acute illness |
| Autoimmune disease on immunosuppressants | Administer before peak season; note blunted response |
Critical contraindication (Updated November 2025):
Live-attenuated influenza vaccine (LAIV) is contraindicated in immunocompromised hosts. LAIV should also be avoided in close contacts of severely immunosuppressed individuals - specifically recent HCT recipients or those with GVHD or SCID.
(IDSA 2025, updated November 18, 2025)
3. RSV Vaccination
Recommendation: All adults and adolescents with compromised immunity should receive RSV vaccination.
Strength: Strong | Evidence: Moderate certainty
Available FDA-authorized RSV vaccines for adults: RSVPreF3 (Arexvy), RSVPreF (Abrysvo), mRNA-1345 (mResvia)
Timing considerations:
- Defer during acute severe immunosuppression or active transplant rejection treatment
- RSV vaccination of household contacts and close contacts is recommended to reduce indirect exposure
For patients under 18 years, RSV vaccination decisions should be individualized through shared decision-making between clinicians and caregivers.
Disease-Specific Guidelines
Malignancy (Cancer Patients)
- Live vaccines: Generally contraindicated during active chemotherapy
- Re-vaccination after chemotherapy: Wait at least 3 months after completion, with evidence of immune reconstitution
- After anti-B-lymphocyte agents (e.g., rituximab): Delay live and some inactivated vaccines by at least 6 months
- Varicella vaccine: Give when in remission ≥3 months after chemotherapy
(Red Book 2021, p. 1287)
Transplant Recipients
Hematopoietic Stem Cell Transplant (HCT)
- Varicella (live): Give as 2-dose series, ≥24 months post-HCT, only if:
- Varicella-seronegative
- No graft-versus-host disease (GVHD)
- Considered immunocompetent
- Last IGIV dose ≥8-11 months prior
- Restart entire vaccine series post-HCT (immunity from pre-transplant vaccines is often lost)
- COVID-19: ≥3 months post-HCT
Solid Organ Transplant (SOT)
- Vaccinate before transplant whenever possible (2+ weeks pre-op ideal)
- Post-transplant live vaccines generally avoided
- Inactivated vaccines: Start ≥1-3 months post-transplant
HIV Infection
| CD4 Status | Vaccines Allowed |
|---|---|
| CD4 ≥200/mm³ (or ≥15% in children) - No severe immunosuppression | MMR, monovalent varicella, inactivated vaccines |
| CD4 <200/mm³ or <15% - Severe immunosuppression | Inactivated vaccines only; NO live vaccines |
| Any HIV patient | MMRV (4-in-1) is never recommended regardless of CD4 count |
(Red Book 2021, p. 1288)
Corticosteroids
- High-dose steroids (≥2 mg/kg/day prednisone or ≥20 mg/day for ≥14 days): Live vaccines contraindicated
- Wait at least 1 month after stopping high-dose steroids before administering live vaccines
- Inhaled, nasal, or topical steroids: Not a contraindication to live vaccines
Herpes Zoster (Shingles) Vaccine in Immunocompromised Patients
A 2024 systematic review and meta-analysis (7 RCTs) found the recombinant zoster vaccine (RZV/Shingrix):
- Reduced herpes zoster incidence by 81% (RR: 0.19, 95% CI: 0.09-0.44) across all ages in immunocompromised individuals
- Significantly boosted both humoral and cellular immunity
- Was more reactogenic (more local/systemic side effects) but with no increase in serious adverse events or death
- Transplant recipients and patients with past malignancy showed lower immunogenicity
Conclusion: RZV should be routinely offered to immunocompromised individuals, preferably before chemotherapy or immunosuppressive treatment. [PMID: 39585863]
NCCN 2024 Guidelines: Cancer Patients
The NCCN Clinical Practice Guidelines v3.2024 (Prevention and Treatment of Cancer-Related Infections) provide specific vaccine guidance for oncology patients. Key points:
- Annual influenza and COVID-19 vaccines recommended for all cancer patients
- Live vaccines avoided during active treatment
- Pneumococcal vaccination with PCV20 or PCV15 + PPSV23 series
- Re-vaccination protocols after stem cell transplant required
[PMID: 39536464]
CAR-T Cell Therapy (Emerging Area)
The American Society of Transplant and Cellular Therapy (ASTCT) Best Practice Considerations (2024) address infection prevention post-CAR-T therapy, including vaccination. This is an evolving area requiring subspecialist guidance. [PMID: 39084261]
Summary Table: Live vs. Inactivated Vaccines
| Vaccine Type | Examples | Immunocompromised |
|---|---|---|
| Live attenuated - contraindicated | MMR, MMRV, Varicella (VAR), LAIV, Yellow fever, BCG, OPV, Rotavirus, Typhoid (oral) | Contraindicated in severe immunosuppression |
| Inactivated - safe | IPV, IIV (flu shot), Hep A, Hep B, DTaP/Tdap, PCV, PPSV23, Hib, Meningococcal, HPV, RZV | Safe; give as scheduled |
| mRNA / subunit | COVID-19 (mRNA, protein subunit), RZV (Shingrix) | Safe; often require extra doses |
Key References
- Nellore A et al. (2026). IDSA 2025 Guidelines on Use of Vaccines for Prevention of Seasonal COVID-19, Influenza, and RSV in Immunocompromised Patients. Clin Infect Dis. doi:10.1093/cid/ciag114 - IDSA Guideline Page
- Marra F et al. (2024). Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations. PLoS One. [PMID: 39585863]
- Rubin M et al. (2024). Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic HCT Recipients. Asian Pac J Cancer Prev. [PMID: 38415523]
- Baden LR et al. (2024). NCCN Clinical Practice Guidelines v3.2024: Prevention and Treatment of Cancer-Related Infections. J Natl Compr Canc Netw. [PMID: 39536464]
- Red Book 2021 - AAP Report of Committee on Infectious Diseases, Table 1.17, pp. 190, 1287-1288
This is a shared conversation. Sign in to Orris to start your own chat.